Fighting fire with fire: Is it time to use probiotics to manage pathogenic bacterial diseases?

John Heineman, Sara Bubenik, Stephen McClave, Robert Martindale

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Probiotics, when considered in clinical practice, have traditionally been used for prophylaxis; however, there is growing data suggesting treatment benefits in numerous disease states. In this review, we focus on probiotics as treatment for and prevention of several acute and chronic infectious processes including Helicobacter pylori, Clostridium difficile, necrotizing enterocolitis, ventilatorassociated pneumonia, vancomycin-resistant enterococci, and nonalcoholic fatty liver disease. It is inaccurate to generalize findings observed in a single probiotic species to all probiotics. This reasoning is due to the variability of colonizing abilities of native intestinal floras, probiotic or otherwise, secondary to different combinations, doses, and duration of treatments. Given these limitations, multiple animal and human studies have shown anti-inflammatory and selective antimicrobial effects of specific probiotics. Some studies suggest a role for probiotics as supplemental treatment, in combination with antibiotics, for the aforementioned disease processes. It is apparent from this review that the efficacy of probiotics is widely variable and multifaceted. More focused clinical and basic science research is necessary to better understand the treatment potential of various probiotics.

Original languageEnglish (US)
Pages (from-to)343-348
Number of pages6
JournalCurrent Gastroenterology Reports
Volume14
Issue number4
DOIs
StatePublished - Aug 2012

Fingerprint

Probiotics
Necrotizing Enterocolitis
Clostridium difficile
Helicobacter pylori
Pneumonia
Anti-Inflammatory Agents
Anti-Bacterial Agents

Keywords

  • Anti-inflammatory
  • Antimicrobial
  • Probiotics
  • Treatment

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Fighting fire with fire : Is it time to use probiotics to manage pathogenic bacterial diseases? / Heineman, John; Bubenik, Sara; McClave, Stephen; Martindale, Robert.

In: Current Gastroenterology Reports, Vol. 14, No. 4, 08.2012, p. 343-348.

Research output: Contribution to journalArticle

@article{e006f4e8805a47cf909a1d9beb5cac8f,
title = "Fighting fire with fire: Is it time to use probiotics to manage pathogenic bacterial diseases?",
abstract = "Probiotics, when considered in clinical practice, have traditionally been used for prophylaxis; however, there is growing data suggesting treatment benefits in numerous disease states. In this review, we focus on probiotics as treatment for and prevention of several acute and chronic infectious processes including Helicobacter pylori, Clostridium difficile, necrotizing enterocolitis, ventilatorassociated pneumonia, vancomycin-resistant enterococci, and nonalcoholic fatty liver disease. It is inaccurate to generalize findings observed in a single probiotic species to all probiotics. This reasoning is due to the variability of colonizing abilities of native intestinal floras, probiotic or otherwise, secondary to different combinations, doses, and duration of treatments. Given these limitations, multiple animal and human studies have shown anti-inflammatory and selective antimicrobial effects of specific probiotics. Some studies suggest a role for probiotics as supplemental treatment, in combination with antibiotics, for the aforementioned disease processes. It is apparent from this review that the efficacy of probiotics is widely variable and multifaceted. More focused clinical and basic science research is necessary to better understand the treatment potential of various probiotics.",
keywords = "Anti-inflammatory, Antimicrobial, Probiotics, Treatment",
author = "John Heineman and Sara Bubenik and Stephen McClave and Robert Martindale",
year = "2012",
month = "8",
doi = "10.1007/s11894-012-0274-4",
language = "English (US)",
volume = "14",
pages = "343--348",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "4",

}

TY - JOUR

T1 - Fighting fire with fire

T2 - Is it time to use probiotics to manage pathogenic bacterial diseases?

AU - Heineman, John

AU - Bubenik, Sara

AU - McClave, Stephen

AU - Martindale, Robert

PY - 2012/8

Y1 - 2012/8

N2 - Probiotics, when considered in clinical practice, have traditionally been used for prophylaxis; however, there is growing data suggesting treatment benefits in numerous disease states. In this review, we focus on probiotics as treatment for and prevention of several acute and chronic infectious processes including Helicobacter pylori, Clostridium difficile, necrotizing enterocolitis, ventilatorassociated pneumonia, vancomycin-resistant enterococci, and nonalcoholic fatty liver disease. It is inaccurate to generalize findings observed in a single probiotic species to all probiotics. This reasoning is due to the variability of colonizing abilities of native intestinal floras, probiotic or otherwise, secondary to different combinations, doses, and duration of treatments. Given these limitations, multiple animal and human studies have shown anti-inflammatory and selective antimicrobial effects of specific probiotics. Some studies suggest a role for probiotics as supplemental treatment, in combination with antibiotics, for the aforementioned disease processes. It is apparent from this review that the efficacy of probiotics is widely variable and multifaceted. More focused clinical and basic science research is necessary to better understand the treatment potential of various probiotics.

AB - Probiotics, when considered in clinical practice, have traditionally been used for prophylaxis; however, there is growing data suggesting treatment benefits in numerous disease states. In this review, we focus on probiotics as treatment for and prevention of several acute and chronic infectious processes including Helicobacter pylori, Clostridium difficile, necrotizing enterocolitis, ventilatorassociated pneumonia, vancomycin-resistant enterococci, and nonalcoholic fatty liver disease. It is inaccurate to generalize findings observed in a single probiotic species to all probiotics. This reasoning is due to the variability of colonizing abilities of native intestinal floras, probiotic or otherwise, secondary to different combinations, doses, and duration of treatments. Given these limitations, multiple animal and human studies have shown anti-inflammatory and selective antimicrobial effects of specific probiotics. Some studies suggest a role for probiotics as supplemental treatment, in combination with antibiotics, for the aforementioned disease processes. It is apparent from this review that the efficacy of probiotics is widely variable and multifaceted. More focused clinical and basic science research is necessary to better understand the treatment potential of various probiotics.

KW - Anti-inflammatory

KW - Antimicrobial

KW - Probiotics

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84865655866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865655866&partnerID=8YFLogxK

U2 - 10.1007/s11894-012-0274-4

DO - 10.1007/s11894-012-0274-4

M3 - Article

C2 - 22763792

AN - SCOPUS:84865655866

VL - 14

SP - 343

EP - 348

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 4

ER -